AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
Amgen(AMGN) Prnewswire·2024-06-05 21:00Amgen(AMGN) Prnewswire·2024-06-05 21:00
R1Amgen(AMGN) Prnewswire·2024-06-05 21:00